24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Diabetes
Resources
Basic InformationLatest News
Mapping IDs Geographic Access Barriers for Diabetic RetinopathyNormal Meal Tolerance Test Is Practical, Reliable in T2DMNo Link to Cognition in Diabetes Prevention Program StudySuicide by Insulin?Promising Start for National Diabetes Prevention ProgramDiabetes Drug Gets FDA Warning Due to Amputation RiskAngela Bassett Puts the Spotlight on Heart HealthAs Temps Rise, Risk of Pregnancy Complication May TooPharmacist-Involved Collaborative Care Benefits T2DMNever Breastfeeding Linked to Increased Risk of T1DMBioengineered Intraabdominal Endocrine Pancreas FeasibleBiomarker ID'd for Pregnancy-Induced Glucose IntoleranceTransplant of Insulin-Producing Cells Offers Hope Against Type 1 DiabetesVitamin D Doesn't Impact Insulin Sensitivity, Secretion in T2DMPCSK9 Linked to New-Onset Diabetes After Renal TransplantLinear Association for Weight Loss, HbA1c Reduction in T2DMHealth Tip: Make Food More FlavorfulAntioxidant Resveratrol May Help Reduce Arteriosclerosis in T2DMHealth Tip: Create a Sick-Day Plan for DiabetesRed Wine Antioxidant Might Help Diabetics' ArteriesCardiometabolic Disease Staging Score Quantifies Diabetes RiskIntense Interval Training Cuts Hypoglycemia Awareness in T1DMDecreased Cortical Thickness Seen in Type 2 DiabetesAlgorithm Integrated Into App Forecasts Glucose LevelsThree Anti-VEGF Treatments Effective for Diabetic RetinopathyType 2 Diabetes May Be Bad for Brain HealthHealth Tip: Coping With the 'Dawn Phenomenon'Plasma Uric Acid Lowering Tied to Drop in Systolic BP in T1DMHealth Tip: Continuous Glucose Monitoring DevicesT2DM Risk Cut by Variant in Sulfonylurea Receptor EncoderObesity Quadruples Kids' Type 2 Diabetes Risk: StudyDoctors Encouraged to Assess Driving Risks for T1DM PatientsEarly Glycemic Control With Metformin Cuts CVD EventsWhen Is It Safe to Drive With Type 1 Diabetes?Nurse-Led Intervention Helps With Diabetes ControlIs Annual Eye Exam a Must for People With Type 1 Diabetes?RUNX1 May Play Role in Proliferative Diabetic RetinopathyFast-Acting Insulin Aspart Ups Glycemic Control in T1DMDiabetes Continues to Be a Significant Public Health BurdenContinuous Glucose Monitoring Improves Quality of Life in T1DMDiabetes Continues Its Relentless RiseContinuous Subcutaneous Insulin Infusion Bests Injections in T2DMPrevalence of Metformin Use 0.7 Percent in PrediabetesENDO: Distinct Urine Metabolite Profile in Obese Youth With T2DMRace Plays Role in Heart, Diabetes Risk, Even at Normal WeightPredictive Low-Glucose Mgmt Cuts Hypoglycemic Events in T1DTeleretinal Diabetic Retinopathy Screening Ups Screening RatesDAPT Cessation Patterns Vary With Diabetes Status After PCIIncreased Use of Newer Meds for Diabetic Nephropathy in the U.S.What Drugs Work Best for Diabetic Nerve Pain?
Links
Related Topics

Medical Disorders

RUNX1 May Play Role in Proliferative Diabetic Retinopathy


HealthDay News
Updated: Apr 17th 2017

new article illustration

MONDAY, April 17, 2017 (HealthDay News) -- The Runt-related transcription factor 1 (RUNX1) gene may play a role in human proliferative diabetic retinopathy (PDR), and upregulation may be a marker of aberrant retinal angiogenesis, according to a study published online April 11 in Diabetes.

Noting that PDR affects those with type 1 and 2 diabetes, and is a common cause of blindness in the developed world, Jonathan D. Lam, M.D., from the Schepens Eye Research Institute in Boston, and colleagues examined the role of RUNX1 in PDR.

The researchers identified RUNX1 as a gene that was upregulated in CD31+ vascular endothelial cells obtained via transcriptomic analysis from human PDR fibrovascular membranes (FVM). Increased RUNX1 RNA and protein expression were seen in response to high glucose in in-vitro studies using human retinal microvascular endothelial cells (HRMECs); HRMEC migration, proliferation, and tube formation were reduced with RUNX1 inhibition. Using immunohistochemical staining for RUNX1, reactivity was seen in vessels of patient-derived FVM and angiogenic tufts in the retina of mice with oxygen-induced retinopathy. Use of the Ro5-3335 small molecule to inhibit RUNX1 activity resulted in significant reduction of neovascular tufts in oxygen-induced retinopathy.

"These findings, including the high glucose-dependent expression of RUNX1, identify a novel pathway of potential therapeutic interest, and implicate RUNX1 in aberrant angiogenesis in multiple conditions," the authors write.

Several authors have filed a provisional patent application on RUNX1 regulation for the treatment of aberrant angiogenesis and proliferative diabetic retinopathy.

Abstract/Full Text (subscription or payment may be required)